5 Key Takeaways
-
1
The Phase 2 VERONA trial demonstrated that the vorolanib intravitreal insert significantly extended the time to first supplemental treatment compared to aflibercept.
-
2
Patients receiving the vorolanib 2.7 mg dose showed a clinically meaningful improvement in best-corrected visual acuity, gaining approximately 7 letters by Week 24.
-
3
The mechanism of action of vorolanib as a tyrosine kinase inhibitor may complement traditional anti-VEGF therapies, suggesting potential for combination treatments.
-
4
EyePoint Pharmaceuticals is conducting Phase 3 trials for EYP-1901, with top-line results expected in 2026, reflecting strong recruitment and interest in the treatment.
-
5
The EYP-1901 insert offers controlled drug release over at least 6 months, potentially reducing the treatment burden for patients with exudative retinal diseases.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.